Have a question or concern? Our dedicated admin team is ready to assist you. Reach us through our social media, telephone, or email.

0121 798 0729


Weight Loss Pens: A Comprehensive Guide To WeGovy vs. Mounjaro

Weight Loss Pens

When it comes to weight loss treatments, two prominent medications have been making headlines: WeGovy (Semaglutide) and Mounjaro (Tirzepatide). Both of these medications are injectable pens designed to help individuals achieve significant weight loss, but they differ in their mechanisms, effectiveness, and availability. Recently all weight loss pens have had a big buzz in the media, with the BBC reporting that these pens also help to reduce Heart Attack risk, by subsequently lowering cholesterol and regulating blood sugar levels. 

WeGovy (Semaglutide)

  • WeGovy is a GLP-1 (glucagon-like peptide-1) receptor agonist. It mimics the GLP-1 hormone, which is naturally produced in the intestines. This hormone helps regulate appetite, leading to reduced food intake.
  • Administered once weekly, WeGovy is prescribed for adults with obesity or those who are overweight with at least one weight-related condition, such as type 2 diabetes or hypertension.

Mounjaro (Tirzepatide)

  • Mounjaro is a dual agonist that targets both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual action helps enhance insulin secretion, improve glycemic control, and significantly reduce appetite, as well as targets Fistula fat.
  • Also administered once weekly, Mounjaro is primarily prescribed for the management of type 2 diabetes but has shown substantial efficacy in weight loss.

How Do These Weight Loss Pens Differ?

The primary difference between WeGovy and Mounjaro lies in their mechanisms of action. While WeGovy solely targets the GLP-1 receptor, Mounjaro targets both GLP-1 and GIP receptors. This dual targeting is believed to provide enhanced benefits in terms of both appetite suppression and the target of fat. 

Which Is More Effective?

In terms of effectiveness, clinical trials have shown that Mounjaro may offer more significant weight loss compared to WeGovy.

  • WeGovy: Participants in clinical trials lost an average of around 15% of their body weight over 68 weeks.
  • Mounjaro: Trials have reported an average weight loss of approximately 15% to 22.5% of body weight over 72 weeks, depending on the dosage.

While both medications are highly effective, Mounjaro appears to provide slightly superior results in terms of weight loss percentages.

Common Side Effects Of Both Weight Loss Pens:

  • Nausea
  • Diarrhoea
  • Vomiting
  • Constipation
  • Abdominal pain

While the side effect profiles are similar, individual experiences may vary. It is essential to discuss any concerns with a healthcare provider, who can help manage side effects and adjust treatment if necessary.

Both WeGovy and Mounjaro offer promising solutions for weight loss, with each having its unique mechanisms and benefits. Mounjaro may offer a slight edge in terms of effectiveness due to its dual receptor targeting, but both medications are effective tools in the fight against obesity. It’s important to consult with a healthcare provider to determine which medication is best suited to your individual health needs and goals. As with any medication, understanding the potential side effects and ensuring availability in your region are crucial steps in making an informed decision.

Click here to book an appointment with one of our doctors.

Share this article
Shareable URL
Prev Post

Rabies Vaccine: Understanding The Importance Of This Vital Vaccination

Next Post

Diabetes: Can I Live a Normal Life?

Leave a Reply

Your email address will not be published. Required fields are marked *

Read next